Merck & Co Inc

-0.42 (-0.53%)
4:00:00 PM EDT: $78.24 -0.03 (-0.04%)
Earnings Announcements

Merck Says Lynparza Reduced Risk Of Death By 31% VS Enzalutamide Or Abiraterone For Men With Brca1/2

Published: 09/20/2020 16:44 GMT
Merck & Co Inc (MRK) - Lynparza Reduced Risk of Death by 31% Versus.
Enzalutamide Or Abiraterone for Men With Brca1/2 Or Atm-mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide Or Abiraterone in Phase 3 Profound Trial.
Merck -astrazeneca & Co Exploring Additional Trials in Metastatic Prostate Cancer Including Ongoing Phase 3 Propel Trial, First Data Expected in 2021.
Revenue is expected to be $12.63 Billion
Adjusted EPS is expected to be $1.60

Next Quarter Revenue Guidance is expected to be $13.46 Billion
Next Quarter EPS Guidance is expected to be $1.79

More details on our Analysts Page.